Clinical Trial Update: RICE-ibrutinib in Relapsed DLBCL [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the RICE-ibrutinib regimen in relapsed or recurrent diffuse large B-cell lymphoma; the current trial status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)
• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Singapore General Hospital | Conditions: Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma Recurrent | Phase 2 | Status: UNKNOWN